Endostatin: The Anti-Angiogenic Peptide That Starves Tumors
Anti-Angiogenic Peptides in Cancer
486 Patients
The largest randomized trial of endostatin enrolled 486 advanced lung cancer patients in China, producing the only regulatory approval this peptide has received anywhere in the world.
Wang et al., Journal of Thoracic Oncology, 2005/2017
Wang et al., Journal of Thoracic Oncology, 2005/2017
View as imageIn 1997, a 20-kilodalton protein fragment isolated from a mouse hemangioendothelioma made the front page of the New York Times. The fragment was endostatin, a naturally occurring piece of collagen XVIII that blocked new blood vessel formation and shrank tumors in mice to microscopic dormancy without observable toxicity.[1] Judah Folkman, the Harvard surgeon who had spent decades arguing that tumors depend on blood vessel recruitment to grow, finally had proof that the body produces its own anti-angiogenic compounds.
Twenty-nine years later, endostatin occupies an unusual position in oncology. It is approved as a cancer therapy in one country (China), failed to show meaningful single-agent activity in US clinical trials, and has generated a renewed wave of research interest through combination strategies with immunotherapy. This article traces endostatin from discovery through clinical development, examines what the data actually shows, and explores where the science is heading. For related coverage, see the cluster articles on how peptides block tumor blood vessel formation and VEGF-targeting peptides.
Key Takeaways
- Endostatin is a 20 kDa C-terminal fragment of collagen XVIII discovered in 1997 by O'Reilly et al. in Judah Folkman's lab at Harvard
- In mice, endostatin regressed primary tumors to dormant microscopic lesions with no detectable toxicity and no drug resistance after repeated treatment cycles
- US Phase II trials showed endostatin was safe but produced no objective tumor responses as a single agent in neuroendocrine tumors (0/40 patients responded)
- China approved recombinant human endostatin (Endostar) for NSCLC in 2005 after a Phase III trial showed improved response rates (35.4% vs 19.5%) and time to progression (6.3 vs 3.6 months) when added to chemotherapy
- Endostatin works through multiple targets: integrin alpha5-beta1, VEGFR2, heparan sulfate proteoglycans, and downstream Src/Ras/Raf signaling cascades
- Current research focuses on combining endostatin with immune checkpoint inhibitors, nanoparticle delivery systems, and gene therapy vectors to overcome its short half-life and improve clinical efficacy
What Is Endostatin?
Endostatin is a 20-kilodalton (184 amino acid) protein fragment cleaved from the C-terminal domain of collagen XVIII, a structural protein found in basement membranes throughout the body. The cleavage is performed by extracellular proteases including cathepsins and matrix metalloproteinases, meaning the body produces endostatin as a natural byproduct of tissue remodeling.
The peptide's sequence contains a zinc-binding domain at its N-terminus that is critical for its anti-angiogenic activity; mutations that disrupt zinc coordination abolish endostatin's ability to inhibit endothelial cell migration. Endostatin circulates in human blood at measurable levels, and its concentration varies in different disease states, suggesting it plays a physiological role in regulating blood vessel growth under normal conditions.
Collagen XVIII is particularly abundant in the vascular basement membrane, the vitreous of the eye, and the liver, which helps explain why endostatin was detectable in culture media from cells that produce abundant extracellular matrix. The fact that the body produces this compound endogenously distinguishes it from synthetic anti-angiogenic drugs like bevacizumab (a monoclonal antibody) and tyrosine kinase inhibitors like sunitinib. This endogenous origin initially generated enormous excitement about its therapeutic potential: if the body already makes a tumor-starving peptide, perhaps boosting its levels could control cancer without the toxicity of conventional chemotherapy. That hypothesis drove a generation of research, though the clinical reality proved far more complex than the original concept suggested.
Discovery: From Hemangioendothelioma to Headlines
The endostatin story begins with Judah Folkman's 40-year hypothesis that tumors cannot grow beyond 1-2 mm without recruiting new blood vessels (angiogenesis). By the mid-1990s, Folkman's lab had already identified angiostatin, another endogenous angiogenesis inhibitor. Michael O'Reilly, working in Folkman's lab, then screened supernatants from an EOMA hemangioendothelioma cell line for anti-angiogenic activity and isolated endostatin.[1]
The 1997 Cell paper reported that systemically administered endostatin regressed Lewis lung carcinoma, T241 fibrosarcoma, and EOMA hemangioendothelioma in mice. Primary tumors shrank to dormant microscopic lesions. Histological analysis showed blocked angiogenesis with balanced proliferation and apoptosis within the residual tumor tissue. No toxicity was observed, and no drug resistance developed across multiple treatment cycles.
These results generated extraordinary media coverage. Nobel laureate James Watson was quoted as saying Folkman would cure cancer within two years. The New York Times ran front-page coverage in May 1998 under the headline "A Cautious Awe Greets Drugs That Eradicate Tumors in Mice." Biotech company EntreMed's stock tripled overnight, adding hundreds of millions of dollars in market capitalization based on mouse data alone. Folkman himself was more measured, famously noting that "if you have cancer and you are a mouse, we can take good care of you." The gap between the mouse data and the media narrative would become one of the most discussed cautionary tales in modern oncology research, illustrating both the power of anti-angiogenic biology and the danger of extrapolating from animal models to human cancer.
How Endostatin Blocks Blood Vessel Growth
Endostatin's mechanism of action involves multiple molecular targets, which distinguishes it from single-target anti-angiogenic drugs like bevacizumab.
Integrin binding. Endostatin binds directly to integrin alpha5-beta1 on endothelial cells, triggering rapid clustering of the integrin with caveolin-1 and activating Src family kinases through a tyrosyl phosphatase-dependent pathway.[2] This destabilizes focal adhesions and actin stress fibers, preventing the cell migration required for blood vessel sprouting. Endostatin also interacts with integrin alpha-v-beta3, another key mediator of angiogenesis.
VEGFR2 inhibition. Endostatin competitively inhibits VEGF receptor 2 (VEGFR2/KDR/Flk-1) binding to its ligand, blocking VEGF-mediated downstream signaling through p38-MAPK, p125FAK, and ERK pathways. This is functionally similar to what bevacizumab achieves by sequestering VEGF itself, but through a different mechanism.
Heparan sulfate proteoglycan binding. Endostatin binds to glypican-1 and glypican-4 on cell surfaces, which modulates growth factor signaling and may contribute to its broad anti-angiogenic profile.
Downstream effects. The combined activity at these targets downregulates RhoA GTPase activity, inhibits Ras/Raf signaling cascades, and ultimately suppresses endothelial cell proliferation, migration, and tube formation. Endostatin also promotes endothelial cell apoptosis through mechanisms that are still being characterized.
This multi-target profile was initially seen as an advantage: by hitting angiogenesis through several independent pathways, endostatin might be harder for tumors to develop resistance against. The mouse data supported this; repeated treatment cycles showed no loss of efficacy. Whether this translates to human cancers remains an open question.
US Clinical Trials: Safe but Ineffective Alone
The transition from dramatic mouse results to human trials produced results that, while not unexpected for oncology, fell far short of expectations. The gap between preclinical promise and clinical reality would become one of the most discussed episodes in modern cancer drug development.
Phase I (2002). Herbst et al. conducted a Phase I trial of recombinant human endostatin administered as daily short intravenous infusions in patients with advanced solid tumors.[3] Among 15 patients receiving 50 monthly treatment cycles, there were no dose-limiting toxicities. One patient with a pancreatic neuroendocrine tumor achieved a minor response. Two patients had disease stabilization. The safety profile was remarkably clean across all dose levels tested, but anti-tumor activity was minimal. The trial's primary contribution was establishing that recombinant endostatin could be administered to humans without significant adverse effects, but it provided little reason for optimism about single-agent efficacy.
Phase II in neuroendocrine tumors (2006). Kulke et al. tested recombinant human endostatin in 42 patients with advanced carcinoid or pancreatic neuroendocrine tumors, administered as twice-daily subcutaneous injections at 60 mg/m2/day.[4] Of 40 evaluable patients, none achieved a partial response. Some patients had prolonged disease stabilization, which is biologically consistent with an anti-angiogenic mechanism (slowing growth rather than shrinking tumors), but the primary endpoint of objective response was zero. The drug was safe and well-tolerated, but the lack of any measurable tumor shrinkage effectively ended enthusiasm for single-agent endostatin in the US oncology community.
Other US/European studies. Additional early-phase trials tested endostatin in various solid tumors including melanoma and sarcoma. Results were similarly underwhelming as monotherapy. The compound consistently demonstrated safety but failed to produce the tumor regressions that had electrified the field after the mouse data.
Several factors contributed to the disconnect between mouse and human results. The recombinant endostatin used in US trials was produced in yeast, yielding a protein that was insoluble and unstable, with a short circulating half-life requiring frequent high-dose administration. The doses achievable in humans may not have matched the mouse-equivalent exposures that produced dramatic regressions. The biology of human tumors, with their genetic heterogeneity, established vasculature, and multiple redundant angiogenic pathways, proved far more resistant to anti-angiogenic monotherapy than transplanted mouse tumor models growing subcutaneously. This "translation gap" would later apply to many anti-angiogenic agents and prompted a fundamental rethinking of how anti-angiogenic therapy should be used: not alone, but in combination with cytotoxic agents.
Endostar: China's Approach That Earned Approval
While US development stalled, Chinese researchers took a different path. Scientists at Simcere Pharmaceutical developed a modified version of recombinant human endostatin with an additional 9-amino-acid tag that improved protein folding, solubility, and stability. This variant, branded Endostar (rh-endostatin, YH-16), could be manufactured cost-effectively in E. coli and maintained biological activity.
A multicenter, randomized, double-blind, placebo-controlled Phase III trial enrolled 486 patients with untreated advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC).[5] Patients received vinorelbine plus cisplatin (NP regimen) with either Endostar or placebo. The study arm (n=322) received NP plus Endostar; the control arm (n=164) received NP plus placebo.
Results: the overall response rate was 35.4% with Endostar versus 19.5% with placebo (P=0.0003). Median time to progression was 6.3 months versus 3.6 months (P<0.001). Clinical benefit rate was 73.3% versus 64.0% (P=0.035). Grade 3/4 adverse events including neutropenia, anemia, and nausea were comparable between arms, indicating Endostar did not meaningfully add to chemotherapy toxicity.
China's State Food and Drug Administration approved Endostar for NSCLC treatment in September 2005. It remains the only regulatory approval for any endostatin product worldwide. The approval was received with skepticism in Western oncology circles for several reasons: the trial was conducted exclusively in Chinese patients, the magnitude of benefit (while statistically significant) was modest compared to the dramatic mouse regressions that had launched the field, and the study design drew questions about double-blinding and outcome assessment standards. Long-term follow-up data published in 2017 confirmed the initial findings but did not demonstrate a statistically significant overall survival benefit, which is the gold standard for cancer drug approval in most regulatory frameworks. Endostar has never been submitted for FDA approval in the United States, and no company has pursued European Medicines Agency registration.
Beyond Lung Cancer: Expanding Clinical Applications
Since its NSCLC approval, Endostar has been tested in several other cancer types in Chinese clinical settings.
Melanoma. A Phase II randomized trial tested Endostar plus dacarbazine versus dacarbazine alone in 110 patients with metastatic melanoma lacking c-kit and BRAF mutations. Median progression-free survival was 4.5 months with Endostar versus 1.5 months with dacarbazine alone, a statistically significant difference, though overall survival data remained immature.
Small-cell lung cancer. A Phase II trial combining Endostar with cisplatin/etoposide chemotherapy in extensive-stage SCLC reported median progression-free survival of 8.0 months, median overall survival of 13.6 months, and an objective response rate of 61.9%.
Concurrent chemoradiation. Multiple studies have combined Endostar with chemoradiation for locally advanced NSCLC, reporting improved response rates and some evidence of reduced radiation pneumonitis, potentially through normalization of tumor vasculature.
These studies share a limitation: nearly all have been conducted in China, predominantly in Chinese patient populations, and many are single-arm or small Phase II designs. Multicenter international trials with diverse populations would strengthen the evidence base considerably. The absence of FDA-registered trials for Endostar reflects both the commercial dynamics of bringing a Chinese-approved drug to the US market and the broader skepticism about endostatin's single-agent activity that persists from the early US trial failures.
One important nuance in interpreting Endostar's benefit across these indications: the peptide is always used in combination with chemotherapy or radiation, making it difficult to isolate endostatin's specific contribution from the overall treatment effect. The Phase III NSCLC trial included a placebo control, which provides the clearest evidence, but smaller studies without placebo arms leave more room for uncertainty. For how other anticancer peptides work to directly kill tumor cells through different mechanisms, see the linked article. The neuroendocrine tumor context is also covered in our article on chromogranin A as a tumor marker.
Endostatin and Immunotherapy: The Emerging Frontier
The most active area of current endostatin research is its combination with immune checkpoint inhibitors. A 2025 review described endostatin's potential to reprogram the immunosuppressive tumor microenvironment (TME), positioning it as a dual anti-angiogenic and immunomodulatory agent.
The rationale: abnormal tumor vasculature creates a hypoxic, immunosuppressive environment that excludes T cells and supports regulatory immune cells. Anti-angiogenic agents like endostatin can "normalize" tumor vessels, improving blood flow, reducing hypoxia, and enabling better immune cell infiltration. This vascular normalization window may synergize with checkpoint inhibitors that unleash anti-tumor T cell activity.
Preclinical data suggests endostatin may also directly influence immune cell function by repolarizing tumor-associated macrophages (TAMs) from the immunosuppressive M2 phenotype toward the anti-tumor M1 phenotype. Additional studies indicate endostatin can reduce the accumulation of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, further tilting the balance toward anti-tumor immunity. If confirmed in clinical settings, these immunomodulatory effects would give endostatin a mechanism of action that extends well beyond simple blood vessel inhibition and could explain synergistic interactions with checkpoint blockade.
Several Chinese clinical trials combining Endostar with PD-1/PD-L1 inhibitors (including pembrolizumab, nivolumab, and camrelizumab) are ongoing or recently completed, but published results from adequately powered randomized comparisons are not yet available. Early case reports and small series have described durable responses in NSCLC patients receiving Endostar plus checkpoint inhibitor combinations, but these observations require validation in controlled trials.
Delivery Challenges and Engineering Solutions
Endostatin's clinical limitations stem largely from its biochemistry. The protein has a short half-life in circulation (estimated 12-13 hours for Endostar), requiring frequent intravenous or subcutaneous dosing. The original recombinant protein was insoluble and unstable, contributing to the US trial failures.
Current approaches to overcome these challenges include nanoparticle delivery systems that encapsulate endostatin for sustained release, gene therapy vectors (adenoviral and lentiviral) that deliver the endostatin gene directly to tumor tissue for continuous local production, and PEGylation strategies that extend circulating half-life.[6] Cell-penetrating peptides have also been investigated computationally as vehicles for intracellular endostatin delivery. A 2024 computational study explored CPP-endostatin fusion constructs that could potentially bypass some of the extracellular degradation that limits endostatin's bioavailability.
Continuous infusion via implanted pumps represents another strategy, based on the observation that endostatin's anti-angiogenic effect requires sustained exposure rather than peak drug levels. This pharmacokinetic profile differs from most chemotherapy drugs and has implications for how clinical trials should be designed.
A multicenter Phase II trial tested a recombinant human endostatin adenovirus (E10A) delivered by intratumoral injection in patients with advanced head and neck carcinoma. The gene therapy approach aims to convert tumor cells into local endostatin factories, maintaining high concentrations at the tumor site without systemic dosing. Early results showed partial responses in some patients, though the approach remains experimental.
The delivery challenge is not unique to endostatin. Many bioactive peptides share similar issues with short half-life, protease degradation, and poor oral bioavailability. The engineering solutions being developed for endostatin delivery have broader implications for the peptide therapeutics field. For deeper coverage of the VEGF pathway specifically, see VEGF-Targeting Peptides. For the broader category of peptides designed to block tumor vasculature, see How Peptides Can Block Tumor Blood Vessel Formation.
The Bottom Line
Endostatin is a naturally occurring 20 kDa collagen XVIII fragment that blocks tumor angiogenesis through multiple molecular targets including integrin alpha5-beta1, VEGFR2, and heparan sulfate proteoglycans. Discovered in Folkman's lab in 1997, it produced dramatic tumor regression in mice but failed as a single agent in US Phase II trials. China's modified version (Endostar) earned NSCLC approval in 2005 based on a 486-patient Phase III trial showing improved response rates and time to progression when combined with chemotherapy. Current research focuses on combining endostatin with immunotherapy and improving delivery through nanotechnology, with the most promising direction being tumor vascular normalization to enhance checkpoint inhibitor efficacy.